000290484 001__ 290484
000290484 005__ 20241111105915.0
000290484 0247_ $$2doi$$a10.3390/ijms25105374
000290484 0247_ $$2pmid$$apmid:38791414
000290484 0247_ $$2pmc$$apmc:PMC11121014
000290484 0247_ $$2ISSN$$a1422-0067
000290484 0247_ $$2ISSN$$a1661-6596
000290484 037__ $$aDKFZ-2024-01111
000290484 041__ $$aEnglish
000290484 082__ $$a540
000290484 1001_ $$00009-0008-4234-5572$$aFellhofer-Hofer, Johanna$$b0
000290484 245__ $$aChemokines as Prognostic Factor in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis.
000290484 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2024
000290484 3367_ $$2DRIVER$$aarticle
000290484 3367_ $$2DataCite$$aOutput Types/Journal article
000290484 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721829722_17462$$xReview Article
000290484 3367_ $$2BibTeX$$aARTICLE
000290484 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000290484 3367_ $$00$$2EndNote$$aJournal Article
000290484 500__ $$aHI-TRON
000290484 520__ $$aChemokines orchestrate many aspects of tumorigenic processes such as angiogenesis, apoptosis and metastatic spread, and related receptors are expressed on tumor cells as well as on inflammatory cells (e.g., tumor-infiltrating T cells, TILs) in the tumor microenvironment. Expressional changes of chemokines and their receptors in solid cancers are common and well known, especially in affecting colorectal cancer patient outcomes. Therefore, the aim of this current systematic review and meta-analysis was to classify chemokines as a prognostic biomarker in colorectal cancer patients. A systematic literature search was conducted in PubMed, CENTRAL and Web of Science. Information on the chemokine expression of 25 chemokines in colorectal cancer tissue and survival data of the patients were investigated. The hazard ratio of overall survival and disease-free survival with chemokine expression was examined. The risk of bias was analyzed using Quality in Prognosis Studies. Random effects meta-analysis was performed to determine the impact on overall respectively disease survival. For this purpose, the pooled hazard ratios (HR) and their 95% confidence intervals (CI) were used for calculation. Twenty-five chemokines were included, and the search revealed 5556 publications. A total of thirty-one publications were included in this systematic review and meta-analysis. Overexpression of chemokine receptor CXCR4 was associated with both a significantly reduced overall survival (HR = 2.70, 95%-CI: 1.57 to 4.66, p = 0.0003) as well as disease-free survival (HR = 2.68, 95%-CI: 1.41 to 5.08, p = 0.0026). All other chemokines showed either heterogeneous results or few studies were available. The overall risk of bias for CXCR4 was rated low. At the current level of evidence, this study demonstrates that CXCR4 overexpression in patients with colorectal cancer is associated with a significantly diminished overall as well as disease-free survival. Summed up, this systematic review and meta-analysis reveals CXCR4 as a promising prognostic biomarker. Nevertheless, more evidence is needed to evaluate CXCR4 and its antagonists serving as new therapeutic targets.
000290484 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000290484 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000290484 650_7 $$2Other$$aCXCR4 expression
000290484 650_7 $$2Other$$achemokine
000290484 650_7 $$2Other$$acolorectal cancer
000290484 650_7 $$2Other$$aoutcome
000290484 650_7 $$2Other$$asurvival
000290484 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000290484 650_7 $$2NLM Chemicals$$aChemokines
000290484 650_7 $$2NLM Chemicals$$aReceptors, CXCR4
000290484 650_7 $$2NLM Chemicals$$aCXCR4 protein, human
000290484 650_2 $$2MeSH$$aHumans
000290484 650_2 $$2MeSH$$aColorectal Neoplasms: pathology
000290484 650_2 $$2MeSH$$aColorectal Neoplasms: metabolism
000290484 650_2 $$2MeSH$$aColorectal Neoplasms: mortality
000290484 650_2 $$2MeSH$$aPrognosis
000290484 650_2 $$2MeSH$$aBiomarkers, Tumor: metabolism
000290484 650_2 $$2MeSH$$aChemokines: metabolism
000290484 650_2 $$2MeSH$$aReceptors, CXCR4: metabolism
000290484 650_2 $$2MeSH$$aDisease-Free Survival
000290484 7001_ $$aFranz, Clemens$$b1
000290484 7001_ $$00000-0002-2610-9667$$aVey, Johannes A$$b2
000290484 7001_ $$aKahlert, Christoph$$b3
000290484 7001_ $$aKalkum, Eva$$b4
000290484 7001_ $$aMehrabi, Arianeb$$b5
000290484 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b6$$udkfz
000290484 7001_ $$00000-0002-0895-4015$$aProbst, Pascal$$b7
000290484 7001_ $$00000-0002-1030-9322$$aKlupp, Fee$$b8
000290484 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms25105374$$gVol. 25, no. 10, p. 5374 -$$n10$$p5374$$tInternational journal of molecular sciences$$v25$$x1422-0067$$y2024
000290484 8564_ $$uhttps://inrepo02.dkfz.de/record/290484/files/ijms-25-05374.pdf
000290484 8564_ $$uhttps://inrepo02.dkfz.de/record/290484/files/ijms-25-05374.pdf?subformat=pdfa$$xpdfa
000290484 909CO $$ooai:inrepo02.dkfz.de:290484$$pVDB
000290484 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000290484 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000290484 9141_ $$y2024
000290484 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2022$$d2023-08-25
000290484 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000290484 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000290484 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000290484 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-07T16:31:47Z
000290484 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-07T16:31:47Z
000290484 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-07T16:31:47Z
000290484 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-07T16:31:47Z
000290484 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000290484 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000290484 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000290484 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000290484 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-25
000290484 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000290484 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000290484 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J MOL SCI : 2022$$d2023-08-25
000290484 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-25
000290484 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-25
000290484 9201_ $$0I:(DE-He78)D196-20160331$$kD196$$lTranslationale Immuntherapie$$x0
000290484 980__ $$ajournal
000290484 980__ $$aVDB
000290484 980__ $$aI:(DE-He78)D196-20160331
000290484 980__ $$aUNRESTRICTED